Edition:
United States

Evotec AG (EVTG.DE)

EVTG.DE on Xetra

7.47EUR
3:29am EST
Change (% chg)

€0.04 (+0.57%)
Prev Close
€7.43
Open
€7.37
Day's High
€7.49
Day's Low
€7.34
Volume
173,738
Avg. Vol
849,581
52-wk High
€7.99
52-wk Low
€2.86

EVTG.DE

Chart for EVTG.DE

About

Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for... (more)

Overall

Beta: 0.78
Market Cap(Mil.): €988.57
Shares Outstanding(Mil.): 133.05
Dividend: --
Yield (%): --

Financials

  EVTG.DE Industry Sector
P/E (TTM): 54.74 44.85 30.38
EPS (TTM): 0.14 -- --
ROI: 7.58 -1.38 14.86
ROE: 9.71 -1.07 16.28

BRIEF-Evotec and Asahi Kasei Pharma enter drug discovery collaboration

* Entered into an integrated drug discovery collaboration with Asahi Kasei Pharma Corporation Source text for Eikon: Further company coverage:

Jan 19 2017

BRIEF-Evotec sees 2016 core profit more than doubling

* Consolidated group revenues up 37% to eur 120.6 m (9m 2015: eur 88.2 m); base revenues up 30% to eur 105.0 m

Nov 10 2016

BRIEF-Evotec teams up with Oxford University

* Says it and oxford create novel partnership called 'lab282'

Nov 10 2016

BRIEF-Evotec plans to acquire Cyprotex for 62 mln eur

* Offer is intended to be implemented by a scheme of arrangement regulated by uk takeover code, with already >50% shares secured irrevocable

Oct 26 2016

BRIEF-Evotec signs deal to cooperate with UCB on in vitro pharmacology

* Under terms of three-year agreement, evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in cns space

Oct 20 2016

BRIEF-Evotec, Carrick Therapeutics agree strategic alliance

* Evotec contributes $6 million to Carrick's $95 million funding round through a top-class global investor consortium

Oct 04 2016

BRIEF-Evotec: further pre-clinical milestone in endometriosis alliance with Bayer

* Says evotec receives further important pre-clinical milestone in endometriosis alliance with bayer

Sep 29 2016

BRIEF-Evotec says enters research collaboration with Inserm in oncology

* Says enters into an oncology research collaboration with Inserm, the private subsidiary of the French National Institute of Health and Medical Research Source text for Eikon: Further company coverage:

Sep 22 2016

BRIEF-Evotec, Bayer to develop new treatments to fight kidney diseases

* Says goal is development of multiple clinical candidates for treatment of kidney diseases such as chronic kidney disease in diabetes patients

Sep 21 2016

BRIEF-Evotec reports 37 pct rise in revenues in H1

* Profitability guidance raised and positive outlook confirmed

Aug 10 2016

Earnings vs. Estimates